Cargando…

Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics

BACKGROUND: Understanding how tumor response is related to relapse risk would help clinicians make decisions about additional treatment options for patients who have received neoadjuvant endocrine treatment for estrogen receptor–positive (ER+) breast cancer. METHODS: Tumors from 228 postmenopausal w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ellis, Matthew J., Tao, Yu, Luo, Jingqin, A'Hern, Roger, Evans, Dean B., Bhatnagar, Ajay S., Chaudri Ross, Hilary A., von Kameke, Alexander, Miller, William R., Smith, Ian, Eiermann, Wolfgang, Dowsett, Mitch
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2008
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556704/ https://www.ncbi.nlm.nih.gov/pubmed/18812550 http://dx.doi.org/10.1093/jnci/djn309

Ejemplares similares

Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial
por: Ellis, Matthew J., et al.
Publicado: (2008)

Postneoadjuvant surveillance and surgery as needed compared with postneoadjuvant surgery on principle in multimodal treatment for oesophageal cancer: a scoping review protocol
por: Schmucker, Christine, et al.
Publicado: (2021)

Who would have thought a single Ki67 measurement would predict long-term outcome?
por: Dowsett, Mitch, et al.
Publicado: (2009)

Short-term presurgical treatment for all?
por: Dowsett, Mitch, et al.
Publicado: (2007)

Leydig Cell Hyperplasia of Ovary – An Unusual Finding in Postneoadjuvant Chemotherapy Case of Primary Fallopian Tube Carcinoma
por: Chaturvedi, Kriti, et al.
Publicado: (2022)

Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer
por: Weigel, Marion T, et al.
Publicado: (2012)

Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2022)

Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation
por: Guest, Stephanie K., et al.
Publicado: (2016)

Predicting pathological complete response by comparing MRI‐based radiomics pre‐ and postneoadjuvant radiotherapy for locally advanced rectal cancer
por: Li, Yuqiang, et al.
Publicado: (2019)

Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
por: Alataki, Anastasia, et al.
Publicado: (2022)

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
por: Dowsett, Mitch, et al.
Publicado: (2018)

Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo
por: Martin, Lesley-Ann, et al.
Publicado: (2012)

Microarray-Based Class Discovery for Molecular Classification of Breast Cancer: Analysis of Interobserver Agreement
por: Mackay, Alan, et al.
Publicado: (2011)

Microarray data analysis in neoadjuvant biomarker studies in estrogen receptor-positive breast cancer
por: Luo, Jingqin, et al.
Publicado: (2010)

Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer
por: Pinhel, Isabel F, et al.
Publicado: (2010)

Problems for risk assessment of endocrine-active estrogenic compounds.
por: Safe, Stephen H, et al.
Publicado: (2002)

Employing multiple synchronous outcome samples per subject to improve study efficiency
por: A’Hern, Roger P.
Publicado: (2021)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Correlation of age and hormone replacement therapy with breast density as assessed by Quantra™
por: Skippage, PL, et al.
Publicado: (2009)

Roles of estrogens, estrogen-like compounds, and endocrine disruptors in adipocytes
por: Lizcano, Fernando
Publicado: (2022)

ENDOCRINE DISRUPTORS: Estrogens in a Bottle?
por: Barrett, Julia R.
Publicado: (2009)

Editorial: Estrogen receptors in endocrine disorders
por: Filardi, Tiziana, et al.
Publicado: (2023)

Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer
por: Sestak, Ivana, et al.
Publicado: (2013)

Initial results of a novel technique of clipped node localization in breast cancer patients postneoadjuvant chemotherapy: Skin Mark clipped Axillary nodes Removal Technique (SMART trial)
por: Lim, Geok Hoon, et al.
Publicado: (2020)

Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer
por: Simigdala, Nikiana, et al.
Publicado: (2016)

The Endocrine Role of Estrogens on Human Male Skeleton
por: Rochira, Vincenzo, et al.
Publicado: (2015)

Non-canonical Estrogen Signaling in Endocrine Resistance
por: Ranganathan, Prathibha, et al.
Publicado: (2019)

Biomarker Genes for Detecting Estrogenic Activity of Endocrine Disruptors via Estrogen Receptors
por: Jung, Eui-Man, et al.
Publicado: (2012)

The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance.
por: Johnston, S. R., et al.
Publicado: (1997)

FOXA1 is a critical determinant of Estrogen Receptor function and endocrine response
por: Hurtado, Antoni, et al.
Publicado: (2010)

Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor–positive breast cancers
por: Ribas, Ricardo, et al.
Publicado: (2014)

Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease
por: Simigdala, Nikiana, et al.
Publicado: (2018)

Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer
por: Barton, S, et al.
Publicado: (2012)

Estrogen receptor degradation: a CUE for endocrine resistance?
por: Musgrove, Elizabeth A
Publicado: (2011)

Toxicity and Estrogenic Endocrine Disrupting Activity of Phthalates and Their Mixtures
por: Chen, Xueping, et al.
Publicado: (2014)

Estrogen Receptors as Molecular Targets of Endocrine Therapy for Glioblastoma
por: González-Mora, Andrea Magali, et al.
Publicado: (2021)

Introduction to sessions on Personalising treatment
por: Dowsett, Mitch, et al.
Publicado: (2007)

Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer.
por: Newby, J. C., et al.
Publicado: (1995)

Defects in mismatch repair: the Achilles heel of estrogen receptor positive breast cancer with intrinsic endocrine therapy resistance?
por: Haricharan, Svasti, et al.
Publicado: (2017)

In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer
por: Lykkesfeldt, Anne E, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_qpqhc6k1ehtcldc6ic7fd3alng